Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02541604 · OUTCOME

Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) in Participants With Neuroblastoma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage
Interval / dispersion
Not reported
Time frame
Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)

Analysis population: Included safety-evaluable population, defined as patients who received any amount of study drug.

Groups in this outcome

Cohort 3

Participants with neuroblastoma.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 311

Reported measurements

Source class 1
Values in Percentage · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 30Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    units
    Participants
groups
  1. description
    Participants with neuroblastoma.
    id
    OG000
    title
    Cohort 3
param Type
NUMBER
population Description
Included safety-evaluable population, defined as patients who received any amount of study drug.
reporting Status
POSTED
time Frame
Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)
title
Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Modified International Neuroblastoma Response Criteria (mINRC) in Participants With Neuroblastoma
type
PRIMARY
unit Of Measure
Percentage

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice